牛牛AI助理已提取核心訊息
On December 21, 2023, Mercer Street Global Opportunity Fund, LLC filed a Schedule 13G with the SEC, disclosing a significant stake in Biodexa Pharmaceuticals PLC. The fund reported ownership of 109,396,800 Ordinary Shares, which includes 46,900,000 shares issuable upon the exercise of warrants, representing a 9.99% ownership in the company. This stake is subject to a beneficial ownership blocker, preventing the fund from exercising warrants that would result in ownership exceeding 9.99% of Biodexa's outstanding Ordinary Shares. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Biodexa Pharmaceuticals. Jonathan Juchno, an authorized representative of Mercer Street Global Opportunity Fund, LLC, has disclaimed beneficial ownership of these securities except to the extent of his pecuniary interest.
On December 21, 2023, Mercer Street Global Opportunity Fund, LLC filed a Schedule 13G with the SEC, disclosing a significant stake in Biodexa Pharmaceuticals PLC. The fund reported ownership of 109,396,800 Ordinary Shares, which includes 46,900,000 shares issuable upon the exercise of warrants, representing a 9.99% ownership in the company. This stake is subject to a beneficial ownership blocker, preventing the fund from exercising warrants that would result in ownership exceeding 9.99% of Biodexa's outstanding Ordinary Shares. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Biodexa Pharmaceuticals. Jonathan Juchno, an authorized representative of Mercer Street Global Opportunity Fund, LLC, has disclaimed beneficial ownership of these securities except to the extent of his pecuniary interest.
2023年12月21日，默瑟街全球機會基金有限責任公司向美國證券交易委員會提交了附表13G，披露了Biodexa Pharmicals PLC的大量股份。該基金報告了109,396,800股普通股的所有權，其中包括行使認股權證時可發行的46,900,000股股票，佔該公司9.99％的所有權。該股份受實益所有權封鎖，這使該基金無法行使認股權證，這將導致Biodexa已發行普通股的所有權超過9.99％。文件顯示，收購這些股份不是爲了改變或影響Biodexa Pharmicals的控制權。默瑟街全球機會基金有限責任公司的授權代表喬納森·尤奇諾聲稱對這些證券擁有實益所有權，但其金錢權益除外。
2023年12月21日，默瑟街全球機會基金有限責任公司向美國證券交易委員會提交了附表13G，披露了Biodexa Pharmicals PLC的大量股份。該基金報告了109,396,800股普通股的所有權，其中包括行使認股權證時可發行的46,900,000股股票，佔該公司9.99％的所有權。該股份受實益所有權封鎖，這使該基金無法行使認股權證，這將導致Biodexa已發行普通股的所有權超過9.99％。文件顯示，收購這些股份不是爲了改變或影響Biodexa Pharmicals的控制權。默瑟街全球機會基金有限責任公司的授權代表喬納森·尤奇諾聲稱對這些證券擁有實益所有權，但其金錢權益除外。
有用
沒用